US pharma major Eli Lilly (NYSE: LLY) has released positive results from pooled subgroup analyses of efficacy data from the Phase III EVOLVE-1 and EVOLVE-2 studies.
These analyses demonstrate a reduction in monthly migraine headache days with calcitonin gene-related peptide (CGRP)-inhibitor Emgality (galcanezumab-gnlm) versus placebo in patients with low- and high-frequency episodic migraine.
Detailed results were presented in an oral platform presentation ( S17.003) at the Annual Meeting of the American Academy of Neurology (AAN) taking place in Philadelphia, USA, on May 6.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze